ACEI inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) do not appear to increase the severity of COVID-19 infections or the risk of death, according to findings of a study published in *JAMA Cardiology*.

This retrospective case series in 1178 patients in Wuhan, China, hospitalised with confirmed COVID-19 infections in March 2020 assessed the association between ACEI or ARB treatment for hypertension and the risks of severe infection and death.

Overall, 30.7% of patients had hypertension and 31.8% of these patients were receiving ACEI/ARB treatment. The rate of death during hospitalisation was 11% overall and 21.3% in patients with hypertension.

The proportion of patients with hypertension receiving ACEI/ARB treatment was similar in those with and without severe infections (32.9% vs 30.7%) and in those who died versus survivors (27.3% vs 33.0%). There were no significant differences in the rates of severe versus nonsevere infection in ACEI users (9.2%  vs 10.1%) or ARB users (24.9% vs 21.2%), or between rates of death versus survival (9.1% vs 9.8% and 19.5% vs 23.9%, respectively).

\"The current findings did not identify an association between treatment with ACEIs/ARBs and either severity or clinical outcomes of COVID-19 hospitalizations in patients with hypertension. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic,\" concluded the authors.
